Sage Journals: Discover world-class research

Abstract

Background

Recent investigations suggest the inclusion of inflammatory markers in the definition of the metabolic syndrome (MS). The aim of this study was to address the role of C-reactive protein, fibrinogen, interleukin-6 (IL-6) and IL-18 (IL-18) on cardiovascular prognosis in accordance to MS.

Methods

A total of 1263 patients with documented coronary artery disease were prospectively included. We defined MS (MS yes: N = 533, 42.2%) as the presence of at least three of the following criteria: triglycerides ≥ 150 mg/dl; low high-density lipoprotein cholesterol (men: < 40 mg/dl women: < 50 mg/dl); body mass index greater than 30 kg/m²; blood pressure ≥ 130/85 mmHg; fasting glucose ≥ 100 mg/dl. In addition, we determined C-reactive protein, fibrinogen, IL-6 and IL-18 levels.

Results

Follow-up data (median 6.1 years) were available for 1257 patients (99.5%). 139 patients (11.1%) died from cardiovascular causes. Cardiovascular mortality was related to MS (MS yes: 15.1% versus MS no: 8.1%, P < 0.0001) and was further increased by elevation of each inflammatory marker. To address whether elevation of inflammatory markers provides additional prognostic information, a subgroup analysis was performed including patients with MS. In a multivariate-adjusted model including all four inflammatory markers, only IL-18 could be identified as an independent predictor of cardiovascular mortality.

Conclusion

The measurement of inflammatory markers, especially IL-18, adds important prognostic information with regard to the long-term prognosis of patients with MS.

Keywords

cardiovascular prognosis inflammation metabolic syndrome

Get full access to this article

View all access options for this article.

References

Larsson

Svardsudd

Welin

Wilhelmsen

Bjorntorp

Tibblin

Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13-year follow-up of participants in the study of men born in 1913. BMJ 1984; 288:1401–1404.

Grundy

SM.

Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 105:2696–2698.

Yudkin

Stehouwer

CDA

Emeis

Coppack

SW.

C-reactive protein in healthy patients: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

Arterioscler Thromb Vasc Biol 1999; 19:972–978.

Visser

Bouter

McQuillan

Wener

Harris

TB.

Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282:2131–2135.

5 Rosito

D'Agostino

Massaro

Lipinska

Mittleman

Sutherland

et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91:683–689.

Wood

Wang

Jenkins

Trayhurn

The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNFα in human adipocytes. Biochem Biophys Res Commun 2005; 337:422–429.

7 Timpson

Lawlor

Harbord

Gaunt

Day

INM

Palmer

et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005; 366:1954–1959.

8 Sattar

Gaw

Scherbakova

Ford

O'Reilly

Haffner

et al. Metabolic syndrome with and without C-reactive protein is a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 2003; 108:414–419.

Ridker

Buring

Cook

Rifai

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 2003; 107:391–397.

10.

Ridker

Wilson

PWF

Grundy

SM.

Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

Circulation 2004; 109:2818–2825.

11.

11 National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults: executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486–2497.

12.

12 Grundy

Cleeman

Daniels

Cleeman

Kahn

; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2005; 112:2735–2752.

13.

Wilson

PWF

Grundy

SM.

The metabolic syndrome. A practical guide to origins and treatment: part I. Circulation 2003; 108:1422–1425.

14.

Pasceri

Willerson

Yeh

ET.

Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102:2165–2168.

15.

Pasceri

Cheng

Willerson

Yeh

ET.

Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531–2535.

16.

Ford

ES.

The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Study. Atherosclerosis 2003; 168:351–358.

17.

Piche

Lemieux

Weisnagel

Corneau

Nadeau

Bergeron

Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005; 96:92–97.

18.

18 Blankenberg

Tiret

Bickel

Peetz

Cambien

Meyer

et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106:24–30.

19.

19 Tiret

Godefroy

Lubos

Corneau

Nadeau

Bergeron

et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005; 112:643–650.

20.

Gerdes

Sukhova

Libby

Reynolds

Young

Schonbeck

Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 195:245–257.

21.

Hung

McQuillan

Chapman

Thompson

Beilby

JP.

Elevated Interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25:1268–1273.

22.

Skurk

Kolb

Muller-Scholze

Rohrig

Hauner

Herder

The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol 2005; 152:863–868.

23.

Herder

Baumert

Kolb

Koenig

Martin

Thorand

Circulating levels of interleukin-18 independently of body fat and fat free mass: results from the MONICA/KORA study. Diabetes Car 2006; 29:174–175.

24.

Tchernof

Nolan

Sites

Ades

Poehlman

ET.

Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002; 105:564–569.

25.

You

Berman

Ryan

Nicklas

BJ.

Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J Clin Endocrinol Metab 2004; 89:1739–1746.

26.

Haffner

Greenberg

Weston

Chen

Williams

Freed

MI.

Effect of rosiglitazone treatment on non traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106:679–684.

27.

27 Yusuf

Hawken

Ounpuu

Bautista

Franzosi

Commerford

et al. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet 2005; 366:1640–1649.

Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome

Abstract

Background

Methods

Results

Conclusion

Keywords

Get full access to this article

References